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Parvovirus 4 in 
Blood Donors, 
France
To the Editor: In the past few 
years, several novel parvoviruses have 
been identiﬁ  ed, including human par-
vovirus B19–related strains V9 and A6, 
and bocavirus. In 2005, parvovirus 4 
(PARV4), a new putative member of 
the family Parvoviridae, was identi-
ﬁ  ed in the plasma of a patient in North 
America who had an acute virus infec-
tion (1). This virus had limited sequence 
homology with parvovirus B19 (<30% 
aa similarity) despite a conserved ge-
nomic organization showing 2 large 
nonoverlapping open reading frames 
(ORF). Phylogenetic studies performed 
with near-complete sequences have 
proposed that human PARV4 can be 
described by ≥3 genogroups (2).
Little information is available 
about the natural history of the vi-
rus, and its clinical role remains un-
known. Initial studies showed that 
PARV4 was present in the blood of 
febrile patients, intravenous drug us-
ers, and persons positive for hepatitis 
C virus or HIV at prevalences of 6%–
30% (3–5). Two recent studies also 
showed the virus in cohorts of kidney 
transplant patients (6,7). PARV4 has 
also been identiﬁ  ed in persons with-
out apparent pathologic changes, such 
as blood donors (1.0%–3.95%), and 
in blood products negative for par-
vovirus B19 DNA (4–6). Virus DNA 
also was found in bone marrow and 
various tissues or organs, suggesting 
possible dispersion of the virus in di-
verse biologic locations (8). 
To provide new insights into the 
dispersion of PARV4 in healthy per-
sons, we assessed the frequency of 
PARV4 viremia in a cohort of blood 
donors by using a dual real-time as-
say. A total of 304 volunteer blood 
donors (154 men; mean age of all 
volunteers 40 years) living in south-
eastern France entered the study. The 
sex ratio (men:women: 1.03) and age 
distribution (19–65 years) of the co-
hort were considered representative 
of the population of blood donors at 
that time. Blood samples were col-
lected in vacuum tubes (Vacutainer, 
SST, Becton Dickinson, Meylan, 
France) and centrifuged, and 1-mL 
plasma aliquots were stored at −80°C 
until use. Nucleic acids were ex-
tracted as described previously (7) 
and tested for PARV4 genomic DNA 
immediately after extraction to avoid 
freezing/thawing cycles.
Five microliters of the eluted 
material served for PARV4 DNA de-
tection using real-time PCR TaqMan 
methods (StepOne Plus, Applied Bio-
systems, Courtaboeuf, France) and 
primers (ORF2) compatible with the 
detection of the 3 virus genogroups 
described at this time (2,4,7). Two 
probes were tested in separate ampli-
ﬁ   cation assays: PARV4-O (5′-FAM- 
TGTTCAACTTTCTCAGGTCCT
ACCGCCC-TAMRA-3′) (4,7) and 
PARV4-N (5′-FAM-TCCTACYGCC
CSCTCCTCCTTCTT-TAMRA-3′). 
The second primer was designed after 
identiﬁ  cation and sequencing of sev-
eral in-house real-time PCR products 
(GenBank accession nos. FJ883557–
61), and more particularly those de-
tectable on agarose gels but showing 
negative signal with PARV4-O Taq-
Man assay because of mismatches 
identiﬁ  ed on the probe recognition site 
(Figure). Ampliﬁ  cation reactions were 
performed as described previously (7). 
Both TaqMan assays were estimated to 
detect as few as 10 copies of PARV4 
DNA per reaction using dilutions of a 
synthetic template (7).
Fifteen (4.9%) blood donors gave 
positive signal with probe PARV4-O; 
62 (20.4%) were positive with probe 
PARV4-N; 6 (2.0%) samples were 
positive in both assays. Overall preva-
lence for PARV4 DNA was 24.0% in 
the blood donors tested.
PARV4 origin of randomly select-
ed PCR products from PARV4-O and 
PARV4-N TaqMan assays (5 each) was 
conﬁ  rmed after cloning and M13 se-
quencing. Point mutations located on 
the PARV4-O recognition site were re-
trieved in amplicons originating from 
samples positive with PARV4-N assay 
(Figure). However, subsequent mo-
lecular studies aiming to characterize 
virus strains were not feasible because 
of the low titer of PARV4 DNA (<500 
copies/mL of plasma) in positive sam-
ples. No speciﬁ  c correlation was iden-
tiﬁ  ed between sex or geographic origin 
and PARV4 viremia, whereas analysis 
of the distribution of PARV4-positive 
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Figure. Alignment of parvovirus 4 (PARV4) sequences showing the location of the 2 probes 
used in the real-time experiments. A) Partial sequences used for the design of probe 
PARV4-N: PARV4 prototype isolate (AY622943) and in-house PCR products characterized 
initially (GenBank accession nos. FJ883557–61). B) Examples of point mutations located 
on the PARV4-O recognition site identiﬁ  ed in amplicons originating from samples positive 
with PARV4-N assay. Mismatches identiﬁ  ed in the alignments are underlined. Nucleotides 
shown in lowercase letters correspond to 5′/3′ ends of the real-time primers. Mismatches 
identiﬁ  ed in the alignments are underlined and in boldface.LETTERS
samples in age groups highlighted a 
relative homogeneity throughout the 
corresponding cohort.
Our study shows that PARV4 in-
fection is readily detectable in French 
blood donors. Prevalence results us-
ing probe PARV4-O were comparable 
to those obtained in previous studies 
involving healthy persons originating 
from various countries (4–6). Con-
versely, the high prevalence obtained 
by using probe PARV4-N was unex-
pected because only 1 study demon-
strated a higher value (45.7%) after 
the investigation of PARV4 DNA in 
bone marrow aspirates of AIDS pa-
tients from Italy (9).
This  ﬁ   nding suggests a larger 
dispersion of PARV4 than expected 
initially in the general population and 
highlights the need for improvement 
in detection systems directed toward 
PARV4 DNA, particularly by inter-
laboratory collaborations, in direct 
connection with studies investigat-
ing PARV4 genetic diversity. These 
considerations are consistent with the 
recent description of a new PARV4 
genogroup in humans and character-
ization of highly divergent variants in 
bovine and porcine species (10). In ad-
dition, such data raise the question of 
the consequent persistence of PARV4 
infection in healthy persons. Future 
studies need to explore both disper-
sion and potential clinical impact of 
PARV4 on infected hosts.  
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Otomastoiditis 
Caused by 
Mycobacterium 
abscessus, 
the Netherlands
To the Editor: Nontuberculous 
mycobacteria (NTM) are increasingly 
recognized as human pathogens (1). 
Otomastoiditis is a rare extrapulmo-
nary NTM disease type ﬁ  rst described 
in 1976; Mycobacterium chelonae–M. 
abscessus group bacteria, which are 
rapidly growing NTM, are the most 
frequent causative agents and the dis-
ease mostly affects children (1–3). 
In the Netherlands, M. chelonae–M. 
abscessus group isolates have been 
reported from the otologic samples of 
an average of 2 patients annually since 
2006, as compared to 6 patients in the 
preceding 10 years. This emergence 
is not a likely result of improved 
laboratory facilities or awareness in 
clinicians because liquid culture and 
molecular identiﬁ  cation  techniques 
predate the rise in notiﬁ  cation  and 
Dutch guidelines advise against per-
forming cultures for chronic otorrhea.
We identiﬁ  ed 10 patients from the 
national reference laboratory database 
with otologic samples yielding M. 
chelonae–M. abscessus group bacteria 
during January 1995–June 2007. We 
resubjected these isolates to molecular 
identiﬁ  cation by rpoB gene sequenc-
ing (4) and performed a medical ﬁ  le 
review.
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